Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526691 · ClinicalTrials.gov registry record · Phase 1
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
A Phase 1 study of Advanced or Metastatic NSCLC, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT04526691: Active Phase 1 study of Advanced or Metastatic NSCLC, sponsored by Daiichi Sankyo.
NCT04526691 is a Phase 1 study of Advanced or Metastatic NSCLC that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 145 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (142% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04526691, a Phase 1 study of Advanced or Metastatic NSCLC, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Datopotamab deruxtecan
- DRUG KEYTRUDA®
Study Locations (20)
Other
- Instituto Europeo Di Oncologica - Milan
- Azienda Ospedaliera San Gerardo - Monza
- Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia - Naples
- National Cancer Center Hospital East - Chiba
- National Cancer Center Hospital - Tokyo
- Showa Medical University Hospital - Tokyo
- H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO) - Barcelona
- START Madrid - Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- (CIOCC-START) Hospital Universitario HM Sanchinarro - Madrid
- Hospital Puerta de Hierro - Majadahonda
Maryland
- Johns Hopkins Kimmel Cancer Center at Bayview - Baltimore
- The Skip Viragh Outpatient Cancer Building - Baltimore
Arizona
- Mayo Clinic - Scottsdale
California
- City of Hope - Duarte
District of Columbia
- Johns Hopkins Kimmel Cancer Center - Washington D.C.
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
New Mexico
- Quantum Santa Fe - Santa Fe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
What the registry record for NCT04526691 still lists
NCT04526691 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (142% higher).
The record links to 1 condition, with Advanced or Metastatic NSCLC appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04526691 names 20 study sites across 9 states, led by Other, Maryland, Arizona.
Frequently Asked Questions
What is clinical trial NCT04526691 about?
NCT04526691 is a clinical study titled "Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)". This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT04526691?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2020-09-15. Estimated completion is 2026-04-15.
What conditions does trial NCT04526691 study?
This clinical trial studies the following conditions: Advanced or Metastatic NSCLC.
What interventions are being tested in trial NCT04526691?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Datopotamab deruxtecan (DRUG), KEYTRUDA® (DRUG).
Who is sponsoring clinical trial NCT04526691?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04526691 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04526691's enrollment target sits among peer trials
145 391st of 2000 higher than 1,607 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI